BreathTIDE PLUS clinical trials: evidence of effectiveness
The research was conducted by certified specialists from the Regenerative Medicine and Nutritional Medicine Department of the European Scientific Society at the Academy of Natural Sciences (Hanover).
To evaluate the effectiveness of the multi-component peptide bioregulator "BreathTIDE PLUS", an analysis was conducted of patient complaints regarding dry cough and shortness of breath during physical exertion and walking, as well as the results of general clinical blood, urine, sputum, and biochemical blood tests. The clinical study involved 10 people (4 women, 6 men), aged 35 to 62, diagnosed with chronic bronchitis in the exacerbation stage, with a disease duration of 12 to 34 years; 6 of these patients were long-term smokers.
During treatment, these individuals additionally used the multicomponent peptide bioregulator "BreathTIDE PLUS". Prior to this, all patients used standard expectorants to promote sputum expectoration. In addition to traditional treatment, patients were prescribed the peptide bioregulator "BreathTIDE PLUS": 2 capsules per day for 45 days. It was found that including the multicomponent peptide bioregulator "BreathTIDE PLUS" in the complex program, along with other treatments for bronchopulmonary diseases, reduced inflammatory manifestations in patients, lessened coughing and shortness of breath, facilitated sputum expectoration, and normalized leukocyte levels.
No adverse effects, complications, or dependence were observed in patients after discontinuation of the bioregulator. No circumstances arose that would necessitate withdrawal of the preparation.
Data collected in 2017.
Source of information: https://myrealway.com/breathtide-plus-forte-peptides-for-respiratory-system
